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Abstract 
The reaction of thiourea with O-perbenzoylated C-(1-bromo-1-deoxy-β-D-
glucopyranosyl)formamide gave the new anomeric spirocycle 1R-1,5-anhydro-D-glucitol-
spiro-[1,5]-2-imino-1,3-thiazolidin-4-one. Acylation and sulfonylation with the corresponding 
acyl chlorides (RCOCl or RSO2Cl where R = tBu, Ph, 4-Me-C6H4, 1- and 2-naphthyl) 
produced the corresponding 2-acylimino- and 2-sulfonylimino-thiazolidinones, respectively. 
Alkylation by MeI, allyl-bromide and BnBr produced mixtures of the respective N-
alkylimino- and N,N’-dialkyl-imino-thiazolidinones, while reactions with 1,2-dibromoethane 
and 1,3-dibromopropane furnished spirocyclic 5,6-dihydro-imidazo[2,1-b]thiazolidin-3-one 
and 6,7-dihydro-5H-thiazolidino[3,2-a]pyrimidin-3-one, respectively. Removal of the O-
benzoyl protecting groups by the Zemplén protocol led to test compounds most of which 
proved micromolar inhibitors of rabbit muscle glycogen phosphorylase b (RMGPb). Best 
inhibitors were the 2-benzoylimino- (Ki = 9 µM) and the 2-naphthoylimino-thiazolidinones 
(Ki = 10 µM). Crystallographic studies of the unsubstituted spiro-thiazolidinone and the above 
most efficient inhibitors in complex with RMGPb confirmed the preference and inhibitory 
effect that aromatic (and especially 2-naphthyl) derivatives show for the catalytic site 
promoting the inactive conformation of the enzyme.  
 
Keywords 
Anomeric spirocycle; thiazolidinone; type 2 diabetes; glycogen phosphorylase; inhibitor; X-
ray protein crystallography; structure-based drug design 
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1. Introduction 
 
A large proportion of clinically used drugs are inhibitors of enzymes and many current drug 
discovery and development efforts aim at the quest of such compounds.1 Finding efficient 
inhibitors for a particular enzyme, and especially increasing the efficacy of such compounds, 
usually makes use of the three dimensional structure of the enzyme in complex with substrate 
analogues, inhibitors, as well as the kinetic and mechanistic behaviour of the enzyme in their 
presence, an approach called rational inhibitor (or drug) design.  
 
Inhibition of glycogen phosphorylase (GP), the main regulatory enzyme of glycogen 
metabolism, has been connected to type 2 diabetes mellitus,2-5 and during the last decade also 
to other diseased states such as myocardial6, 7 and cerebral8, 9 ischemia as well as tumors10-13 
as amply discussed in recent reviews and primary research articles. Liver and muscle isoforms 
of GP have been thoroughly characterized, the structural features of the proteins and the 
binding sites are well known and have been surveyed,14, 15 therefore these enzymes are ideal 
targets for rational and structure-based inhibitor design. 
 
Several structural classes of compounds for inhibition of GP have been designed and 
evaluated2, 5, 16 (mostly with the prototype of GP14 isolated from rabbit muscle (RMGPb)) 
among which the most populated group is that of the glucose analogues which bind mostly at 
the catalytic site.14, 15, 17 The evolution of some glucose based compounds leading to the first 
low micromolar inhibitor of GP is exemplified in Chart 1 by compounds A-C. Thus, 
introduction of an acylamino type substituent in the β-anomeric position of A to give B 
resulted in enhanced binding by more than one order of magnitude. Formal ring closure of the 
substituents to yield spiro-hydantoin C gave an inhibitor even more efficient than B. 
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Synthesis of the essentially equipotent spiro-thiohydantoin D proved much simpler18 than that 
of C, and D was shown to have considerable in vivo effects in lowering blood sugar levels.19  
 
The structural features responsible for the strong binding of the spiro-hydantoins C and D to 
RMGPb were established by X-ray crystallography, and summarized as follows:20, 21 a) a 
hydrogen bond exists between the β-NH group of the hydantoin and the main chain oxygen of 
His377; b) the rigid planar spiro-hydantoin moiety undergoes little loss of conformational 
entropy on binding; c) the hydrogen bonding capability of the hydantoin polar groups exploit 
existing water structure and recruit new waters to complete networks to protein atoms, 
thereby providing additional enthalpic interactions.  
 
The first submicromolar glucose derived inhibitor of GP (E in Chart 1) was found among N-
acyl-N’-β-D-glucopyranosyl ureas.17, 22 In this series X-ray crystallography of the enzyme-
inhibitor complexes2, 23 indicated the absence of the above mentioned hydrogen bond between 
the β-NH group and His377 O; therefore, the stronger binding was attributed to extensive 
interactions with the large aromatic appendage of the inhibitor in the so-called β-channel of 
the protein. A variant of E with a 3,5-dimethyl-phenyl group in place of the 2-naphthyl 
moiety was shown to improve glucose tolerance and to rearrange hepatic metabolism in 
diabetic mice.24 
 
These observations shifted the focus of inhibitor design towards interactions in the β-channel 
and led to new principles25 stating that efficient inhibitors advantageously have a rigid 
spirobicyclic scaffold which should not necessarily have an H-bond donor towards His377 
(although this can be beneficial if available), but a suitably oriented, large aromatic 
substituent must be present to fit into the β-channel. These principles were first validated by 
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the synthesis and enzymatic evaluation of glucopyranosylidene-spiro-oxathiazolines25, 26 (e. g. 
F in Chart 1) and further corroborated by spiro-isoxazolines27 G among which the 2-naphthyl 
derivatives proved to be nanomolar inhibitors. 
 
 
Taking into account the above design principles and the importance of the hydrogen bond 
forming capacity of the polar groups in the inhibitor molecules as proven for the spiro-
hydantoins, here we report on the synthesis of glucopyranosylidene-spiro-
iminothiazolidinones (target compounds in Chart 1) which have, in comparison to F and G, 
additional polar moieties in the α-position of the sugar ring. These compounds have been 
tested for their inhibitory effects towards RMGPb by enzyme kinetic assays and, for selected 
inhibitors, crystallographic methods.  
 
Chart 1. Inhibition of GP by selected derivatives of D-glucose (Ki [µM] against RMGPb) 
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2. Results and discussion 
 
2.1. Synthesis 
 
Reactions of α-halogen carbonyl compounds with thioamides are generally used for the 
construction of the thiazole ring. As a variant of the method, α-halogen carboxylic acid 
derivatives (most often esters) and thiourea (or its substituted derivatives) can be reacted to 
give 2-imino-thiazolidin-4-ones or the tautomeric 2-amino-∆2-thiazolin-4-ones.34 The latter 
reaction type is exemplified by some syntheses of spiro-thiazolidinones.35-38 Related 
spirobicyclic systems containing a sugar ring are very scarce: to the best of our knowledge a 
ribofuranosylidene-spiro-thiazolidine-2,4-dione39 and epimers of galactopyranosylidene-
spiro-thiazolidine-2,4-dithione as well as galactopyranosylidene-spiro-2-amino-∆2-thiazolin-
4-thione40 were reported.  
 
Since the above ribofuranosylidene-spiro-thiazolidine-2,4-dione39 was prepared by reacting 
O-perbenzoylated 1-bromo-D-ribofuranosyl cyanide with thiourea, in our first attempts 
similar reactions of the analogous glucopyranosyl compound 118 (Table 1) were tried. 
Unfortunately, no reaction took place under the reported conditions39 (1.3-2 equiv of thiourea, 
EtOH-sulfolane solvent mixture, 100 ºC) either with conventional or microwave heating. 
Changing the solvent to nitrobenzene or DMF and raising the reaction temperature to 150 ºC 
brought about no transformation while in N-methylpyrrolidone or ethylene glycol only 
decomposition could be observed. 
 
The next trials were performed with the conventionally used α-halogen ester type compounds 
2 and 341 (Table 1, Entries 1-4). Under microwave heating conditions the desired spiro-
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thiazolidinone 5 was obtained albeit the conversion of the starting compounds was 
incomplete. The active ester 3 showed somewhat higher reactivity (Entry 3). In a parallel 
experiment (Entry 5) the α-bromo carboxamide type 418 was also shown to be converted to 5. 
Since the preparation of 4 is shorter than those of 2 and 3 further optimizations (Entries 5-10) 
were carried out with this compound (as far as we know this type of cyclization with α-
halogen carboxamides is unknown in the literature). Although the conversion of the starting 
material remained incomplete in these experiments, under the best conditions (Entries 7 and 
10) approx. 75-80 % of 4 could be transformed into 5 by using large excess of thiourea. 
Removal of the sugar protecting groups was effected by the Zemplén protocol to give the 
unprotected 6 in acceptable yield.  
 
Structural elucidation of 5 was based on NMR methods. Complete assignments of protons and 
carbons were made by COSY and HSQC correlations. The 4C1 conformation of the 
glucopyranose ring followed from the vicinal proton-proton coupling constants. The 1H NMR 
spectrum showed the presence of a broad singlet at 10.8 ppm for N(3)H, while the signal for 
C(2)=NH was hidden among the aromatic CH resonances (for comparison the NH signals for 
CONH2 of 4 appeared as 2 broad singlets between 5-7 ppm). The 13C NMR spectrum 
exhibited a resonance at 183.0 ppm for C(4), and another one at 179.7 ppm for C(2). 
Carbonyls of the protecting groups appeared as expected. The configuration of the spiro 
carbon C(1’) was established on the basis of three-bond heteronuclear coupling between H(2’) 
and C(4). This coupling was measured by a sensitivity enhanced gradient long-range 13C-1H 
correlation experiment (G-HSQMBC) and the obtained ~5.9 ± 0.3 Hz value indicated trans 
arrangement of the relevant atoms in the 4C1 conformation. Cross peaks were observed also 
between N(3)H and C(1’), C(4) and C(2), but C(2)=NH gave a cross peak only with C(2), 
thereby corroborating ring formation. 
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Table 1. Preparation of glucopyranosylidene-spiro-iminothiazolidinone 
2  X = OMe
3  X = OC6Cl5
4  X = NH2
O
BzO
BzO
BzO
OBz
Br
COX O
BzO
BzO
BzO
OBz
N
H
S
O
NH
O
HO
HO
HO
OH
N
H
S
O
NHMeOH, rt
NaOMe (cat.)
5 6
51 %
S C(NH2)2
O
BzO
BzO
BzO
OBz
Br
CN
S C(NH2)2 no reaction or decomposition
1
see text
for other conditions
1'
2'3'
4' 5'
6'
1
2
34
5
 
Entry Starting 
compound 
Solvent Thiourea 
(equiv.) 
Temp. 
(ºC) 
Heating Reaction 
time 
Conversion of 
starting compd. 
(%) 
Yield of 
5 (%) 
1. 2 acetone 1.5 95 MW/150W 30 min 41 99 
2. 2 EtOH 1.5 95 MW/100W 30 min 42 99 
3. 3 acetone 1.5 95 MW/150W 30 min 80 55 
4. 3 EtOH 1.5 95 MW/100W 30 min 50 99 
5. 4 acetone 1.5 reflux oil bath 12 h 54 76 
6. 4 acetone 2.5 reflux oil bath 7 days 72 82 
7. 4 acetone 12 rt - 11 days 89 86 
8. 4 EtOH 12 rt - 11 days 80 81 
9. 4 EtOH 1.5 95 MW/100W 30 min 43 61 
10. 4 EtOH 10 120 MW/100W 1 h 82 97 
 
 
In order to introduce a substituent to approach the β-channel of the enzyme acylation was 
investigated first (Scheme 1). A series of aliphatic and aromatic carboxylic acid chlorides and 
arenesulfonylchlorides were used to get carboxamides 7-13 and sulfonamides 14-17, 
respectively, in medium to good yields. In these reactions only the the C(2)=NH group was 
substituted as revealed by broad singlets between 9-12 ppm for N(3)H of the 
iminothiazolidinone ring. Configuration of the C=N double bond was not investigated at this 
stage, but the single series of signals in the NMR spectra indicated formation of one isomer 
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only. This structural feature was later deduced from the crystallographic investigation of the 
enzyme-inhibitor complexes. O-Debenzoylation under Zemplén conditions resulted in a loss 
of the N-acyl moiety from 7 and 8 furnishing thiazolidinone 6. Deprotection of 9-13 gave the 
corresponding 18-22 in modest yields, probably because of the sensitivity of the 
carboxamides to the slightly basic conditions, while sulfonamides 14-17 gave the O-
unprotected 23-26 in almost quantitative yields. 
 
MeOH, rt
NaOMe (cat.)RCl
dry pyridine,
rt
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S
O
NH
5
O
BzO
BzO
BzO
OBz
N
H
S
O
N
7-17
O
HO
HO
HO
OH
N
H
S
O
N
18-26
RR
 
 R    Yield (%)   Yield (%) 
 Me-CO   7 76  thiazolidinone 6 (R = H) 20 
 iPr-CO   8 81  thiazolidinone 6 (R = H) 61 
 tBu-CO   9 82  18 26 
 Ph-CO   10 84  19 58 
 4-Me-C6H4-CO   11 53  20 43 
 1-naphthyl-CO   12 73  21 56 
 2-naphthyl-CO   13 89  22 50 
 Ph-SO2   14 55  23 98 
 4-Me-C6H4-SO2   15 70  24 97 
 1-naphthyl-SO2   16 45  25 96 
 2-naphthyl-SO2   17 62  26 98 
Scheme 1. Acylation of glucopyranosylidene-spiro-iminothiazolidinone 5 
 
Alkylation of 5 was studied with various alkyl halides in the presence of K2CO3 in DMF 
(Scheme 2). Methyl iodide gave only a single product 27 for which the presence of the methyl 
group attached to N(3) was indicated by the absence of the broad singlet of the corresponding 
proton around 10 ppm. Reactions with allyl or benzyl bromides resulted in mixtures of 
monoalkylated products 28 and 30 as well as dialkyl derivatives 29 and 31, respectively, 
which could be separated by column chromatography. α,ω-Dibromoalkanes furnished good 
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yields of the ring-annelated compounds 32 and 33 which were deprotected by the Zemplén 
method to give 34 and 35 in acceptable yields. The position of the alkyl group in compounds 
27, 28, and 30 followed from the absence of the broad singlet of N(3)H. In the proton spectra 
of the dialkylated compounds 29 and 31-33 no NH signals could be observed. Aliphatic and 
additional aromatic resonances for the introduced groups appeared as expected. 
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Scheme 2. Alkylation of glucopyranosylidene-spiro-iminothiazolidinone 5 
 
 
2.2. Enzyme kinetic studies and structure-activity relationships 
 
The new compounds were evaluated for their inhibitory potency against RMGPb. The kinetic 
studies were performed in the direction of glycogen synthesis and the results obtained are 
summarized in Table 2. Thiazolidinone derivative 6 proved to be a low micromolar inhibitor, 
however, a comparison to spiro-hydantoins C and D in Chart 1 shows that 6 is 5-8 times less 
efficient than the hydantoins. This may be due to the loss of the direct H-bridge to His377 
carbonyl oxygen shown to be crucial in the binding of the hydantoins to the enzyme. 
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Acylation of 6 at the exocyclic NH gave inhibitors of varying efficiency depending on the 
structure of the acyl group. While the large pivaloyl moiety of 18 was not beneficial for the 
inhibition resulting in a more than 5-fold weakening of the binding compared to that of the 
parent 6, the aromatic groups in 19, 21, and 22 made the inhibition ~2 times stronger. 
Somewhat unexpectedly, however, these aroyl derivatives had rather similar inhibition in 
contrast to observations with inhibitor types E-G in Chart 1, where the size and orientation of 
the aromatic part had a strong bearing on the inhibition generally rendering the 2-naphthyl 
compounds to be the best inhibitors.17 Introduction of a methyl group in the 4-position of the 
phenyl ring as in 20 resulted in a weaker inhibition than that of 19, and this is again different 
from compounds E-G in which this modification (or 4-OMe substitution) gave more effective 
inhibitors.17, 22 This behaviour may reveal a rather unfavourable orientation of the aromatic 
part of these compounds in the active site β-pocket of the enzyme.  
 
Sulfonylation of 6 as in compounds 23-26 gave inhibitors of still micromolar efficiency, 
however, these proved weaker than 6 and were pairwise less efficient than their acylated 
counterparts 19-22, respectively. This may be due to the presence of the tetrahedral sulfonyl 
linker which can force the aromatic ring in more unfavourable positions than in the acylated 
derivatives. Similar phenomena were observed on introduction of CH2 or SO2 groups17, 42 in 
place of planar moieties of inhibitors of type E in Chart 1 as well as in analogous compounds.  
 
Extension of 6 by annelating a further ring to the thiazolidinone gave practically inactive 
compounds 34 and 35 showing that increasing the size of the molecules in this particular 
direction, being obviously out of the direction of the β-channel, is highly detrimental for the 
binding.  
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Table 2. Inhibition of RMGPb by the new 
spirocyclic compounds 
O
HO
HO
HO
OH
N
H
S
O
N
R
 
 
 
R Ki [µM] 
6 H 24 ± 1.7 
18 tBu-CO 137 ± 15* 
19 Ph-CO 9 ± 0.6* 
20 4-Me-C6H4-CO 35 ± 3.1 
21 1-naphthyl-CO 15 ± 1.1* 
22 2-naphthyl-CO 10 ± 1* 
23 Ph-SO2 143 ± 21* 
24 4-Me-C6H4-SO2 63 ± 5 
25 1-naphthyl-SO2 29 ± 3.7 
26 2-naphthyl-SO2 153 ± 23 
O
HOHO
HO
OH
N
S
O
N
 
   34 
48 % 
inhibition  
at 1 mM 
O
HOHO
HO
OH
N
S
O
N
 
   35 
No inhibition 
up to 1 mM 
*Calculated from the IC50 values by the Cheng-Prusoff 
equation:43 Ki = IC50/(1 + [S]/Km). 
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2.3. Crystallographic studies 
 
Structural studies were performed for the parent spirocycle 6 and the two best inhibitors of the 
series (19, 22). The crystal structures of RMGPb:6, RMGPb:19, and RMGPb:22 were 
determined at high resolution 1.95 Å, 1.90 Å, and 2.1 Å, respectively using mainly 
synchrotron radiation at Daresbury Laboratory, UK. The data collection and processing 
statistics along with those from refinement and model quality are summarized in Table 3S. 
Crystallographic numbering for 6, 19, and 22 is shown in Tables 4S, 7S, and 10S respectively.  
 
The results showed that all three compounds bound at the catalytic site of the enzyme as 
indicated by the difference electron density maps (Figure 1).  
 
 
Figure 1. Schematic representation of the 2Fo - Fc electron density maps contoured at 1.0 σ 
level of the refined complex structures of RMGPb:6 (left), RMGPb:19 (middle), and 
RMGPb:22 (right) of the enzyme. The figure was prepared with UCSF Chimera.44  
 
 
More specifically, 6 forms a total of 16 hydrogen bond and 78 van der Waals interactions 
upon binding (Figure 2) most of which come from the sugar peripheral hydroxyl groups. 
Comparison with the RMGPb-glucopyranosylidene-spiro-hydantoin (C in Chart 1) complex 
structure determined previously20, 45 showed that replacement of N-1 (cf formula C in Chart 1) 
with sulfur resulted in less favourable binding compared to spirohydantoin C. In agreement 
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with the kinetic results obtained, the ligand affinity was reduced. As discussed in the 
introduction, an H-bond from an NH group to the carbonyl oxygen of His377 could be 
considered added value for improved affinity for a number of glucose derivatives; however, it 
was not a prerequisite for strong binding. Therefore, the weaker binding could not be 
attributed solely to the loss of the hydrogen bond formation. Careful inspection of the residues 
in the ligand environment after superposition of the three dimensional complex structure of 
RMGPb:6 on RMGPb:spirohydantoin showed that the atoms of the spiro heterocycle have 
shifted by ~0.5 Å (an incline by ~16°) while the carbonyl oxygen of His377 has moved away 
by ~0.4 Å from its original position. The repulsive forces which might develop between the 
sulfur atom inserted in the spiro ring and the backbone oxygen of His377 (at a distance of 3.3 
Å) could partially explain the worse inhibition of enzyme activity despite the increased 
number of interactions formed (two additional hydrogen bonds and eight van der Waals 
interactions). In addition, it was anticipated that substitution of the carbonyl oxygen at 
position (2) of the spiro ring (cf C in Chart 1 and 5 in Table 1) with an NH group would have 
improved the affinity. However, it seems that this NH forms water-mediated interactions with 
the 280s loop residues equivalent to those of the carbonyl oxygen in the 
RMGPb:spirohydantoin complex structure (Tables 4S-6S, Figure 2).45 To achieve this, the 
solvent structure is slightly perturbed (shifts by ~0.4 Å are observed) and the most profound 
change is that of Wat53 O, that forms a direct H-bond with N1 of 6 and shifts by ~0.9 Å to 
optimize its contact with Asp283 OD1. The atoms of both residues Asp283 and Asp284 also 
move by ~ 0.4 Å.  
 
The three dimensional structure of 19 in complex with RMGPb provided further evidence on 
the preference of the so-called ‘β-pocket’ of the catalytic site for aromatic groups, as long as 
they are oriented across the β-channel. Compound 19 binds tightly at the catalytic site 
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forming a favourable network of interactions (19 hydrogen bonds and 109 van der Waals 
interactions (Tables 7S-9S, Figure 3)). These interactions seem to outweigh the alterations of 
the solvent structure induced upon binding which is also supported by the entropic effect 
introduced by the release of water molecule. The slightly worse inhibition potency that it 
exhibits compared to the lead compound spirohydantoin of glucopyranose (Table 2), might be 
both due to the sulfur atom introduced in the spiro ring, similar to 6, but also due to the 
perturbation of the solvent structure to accommodate the phenyl ring. Water 60 O of 
RMGPb:6 is not present in the new complex structure, destabilizing the side chain of Asp339 
(dihedral χ2 rotates by ~40 °), and Wat55 O shifts by ~1.0 Ǻ to move away from the phenyl 
ring. Minor changes are observed in the side chain of His341 (imidazole ring atoms shift by 
~0.3 Ǻ to ~0.5 Ǻ (Figure 4). The increased number of van der Waals interactions formed with 
residues in the vicinity seems to outweigh the energy loss due to these alterations.  
 
 
Figure 2. LIGPLOT diagram of 6 interacting with the active-site residues lying in the 
vicinity. Hydrogen bonds are shown as dark green dashed lines. Additional residues forming 
van der Waals interactions with the ligand are represented by red semicircles with radiating 
spokes.46 Water molecules are depicted in cyan as round spheres. 
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Figure 3. LIGPLOT diagram of 19 interacting with the active-site residues lying in the 
vicinity. Hydrogen bonds are shown as dark green dashed lines. Additional residues forming 
van der Waals interactions with the ligand are represented by red semicircles with radiating 
spokes.46 Water molecules are depicted in cyan as round spheres. 
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Figure 4. Superposition of the crystal structures of RMGPb in complex with spirohydantoin 
(C in Chart 1, shown in orange), with RMGPb:19 (shown in cyan) bound at the catalytic site 
of the enzyme. The figure was prepared with program MolSoft.47  
 
 
Replacement of the phenyl ring of 19 with a 2-naphthyl group resulted in compound 22 that 
was also studied in complex with RMGPb. X-ray diffraction data collected at 2.1 Å resolution 
slightly lower compared with the previous two complex structures. As it was anticipated, the 
difference electron density maps (Figure 1, right) confirmed that compound 22 also binds at 
the catalytic site of the enzyme and the 2-naphthyl group is accommodated in the so-called β-
subsite, in accordance with previous compounds with such a substituent.2 
 
A portion of additional electron density was observed at the new allosteric site of the enzyme 
that could be attributed to the 2-naphthyl group only. Previous studies have shown that 
glucose analogues bearing this group bound at both the catalytic and the new allosteric site. 
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The compound was incorporated in the model of the complex structure and was subjected to 
refinement. The resulting density was not satisfactory, suggesting that the compound binds, 
very weakly though, at the new allosteric site so 22 was not included as a ligand at this site. A 
portion of continuous electron density observed in the vicinity of the active site, above the β-
subsite were the 2-naphthyl group was located, was attributed to dithiothreitol (DTT) that was 
used during the enzyme isolation and purification process (for details see Supporting 
information and Figure 5). 
 
Detailed investigation of the binding mode of 22 and comparison with 19 revealed that there 
are structural changes at the catalytic site of the enzyme induced by changes that might also 
facilitate the binding of DTT. More specifically, 22 forms a total of 17 hydrogen bonds and 
126 Van der Waals interactions which are summarized in Tables 10S-12S and graphically 
presented in Figure 5. 
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Figure 5. LIGPLOT diagram of 22 (top) interacting with the active-site residues lying in the 
vicinity. The interactions formed by DTT at the same site are also shown (bottom) Hydrogen 
bonds are shown as dark green dashed lines. Additional residues forming van der Waals 
interactions with the ligand are represented by red semicircles with radiating spokes.46 Water 
molecules are depicted in cyan as round spheres. 
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Superposition of the crystal structures of RMGPb:22 with RMGPb:19 bound at the catalytic 
site of the enzyme (Figure 6) showed that replacement of the phenyl group by the 2-naphthyl 
one led to significant changes at the catalytic site, especially in the residues lining the 280s 
loop (282-287). More specifically, three water molecules Wat159 O, Wat160 O, Wat161 O 
and Wat162 O are displaced to avoid steric interaction with the ligand 2-naphthyl group. This 
re-arrangement is accompanied by flipping of the peptide bond between Asn282 and Asn283 
~180° and rotation of their dihedral angles; Asn282 (χ1, χ2) rotate by (~98°, 24°), respectively 
and Asp283 dihedral angle χ2 to rotates by 116°. The perturbation of the 280s loop residues 
includes Asn284, the backbone atoms of which shift by 0.7 to 0.9 Ǻ and its side chain 
changes also changes conformation (dihedral angles (χ1, χ2) rotate by (~28°, 42°)). The 
phenylalanine residues Phe285 and Phe286 also participate in the consecutive changes 
induced by shifts of their backbone atoms (ranging from ~0.5 to 0.9 Ǻ) and similarly, Glu287 
that alters its conformation substantially (dihedrals (χ1, χ3) rotate by (~70°, 114°)) and the 
orientation of the peptide bond it forms with Gly288. The latter is correlated with the presence 
of a DMSO molecule that binds in the vicinity of Glu287 at a position previously occupied by 
a water molecule (Wat162 O in RMGPb:19 complex structure) at the β-subsite of the catalytic 
channel. The presence of the DMSO molecule appears to further stabilize the perturbed 280s 
loop residues in their new position. The more hydrophobic part of 22 is lying now closer to 
the 280s loop increasing the number of van der Waals interactions (Table 12S) and creating 
more space at the opposite side of the catalytic site. This allowed the binding of DTT that 
displaced two water molecules Wat165 O and Wat166 O and induced changes in the Asp339 
side chain (dihedrals (χ1, χ3) rotate by (~38°, 84°)) and main chain atoms (shifts by ~0.6 Ǻ). 
Similar amendments take place in the environment of Asp339 starting from Asn388 
(backbone atoms shift by ~0.5 A and dihedral angle χ1 rotates by ~20°) affecting Leu136 side 
chain (rotation of dihedral angle χ2 by ~96°). In addition, all atoms of the 380s loop (378-
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380) are subjected to minor shifts by 0.4-0.5 Ǻ. Finally, His341 ring inclines by ~35° so as to 
optimize the stacking interactions between the aromatic moiety of the ligand and the 
imidazole ring. Overall, despite the slightly reduced hydrogen bond interactions formed in the 
RMGPb:22 complex upon binding of the ligand, and the re-organization of the β-pocket at the 
active site of the enzyme, it appears that compound 22 is tightly bound at the catalytic site of 
the enzyme in agreement with the kinetic results. The presence of DMSO and DTT seem also 
to have facilitated this binding.  
 
 
 
Figure 6. Superposition of the crystal structures of RMGPb:19 (shown in cyan) with 
RMGPb:22 (shown in mauve) bound at the catalytic site of the enzyme. The figure was 
prepared with program MolSoft.47  
 
Comparison of all three ligands showed that their location and orientation at the active site of 
the enzyme is very similar (Figure 7). In particular, the small incline in the spiro ring 
observed when one of its nitrogen atoms was replaced by a sulphur atom allowed the ligands 
to bind along the β-channel by orienting their most hydrophobic groups to optimally interact 
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with residues lining this subsite. This is clearly shown for all ligands including compound 22, 
in which the position of almost all atoms is also maintained except for the naphthyl group that 
needs to optimise its interaction with the 280s loop residues. 
 
 
Figure 7. Superposition of spirohydantoin (C in Chart 1, shown in orange) and the ligands 6 
(shown in green), 19 (shown in cyan) and 22 (shown in mauve) bound at the corresponding 
RMGPb complex structures. The figure was prepared with program MolSoft.47  
 
 
3. Conclusion 
 
A new spirobicyclic ring system 1R-1,5-anhydro-D-glucitol-spiro-[1,5]-2-imino-1,3-
thiazolidin-4-one (6) was obtained in the reaction of C-(2,3,4,6-tetra-O-benzoyl-1-bromo-1-
deoxy-β-D-glucopyranosyl)formamide and thiourea. Alkylation, acylation, and sulfonylation 
gave further functionalized derivatives of the anomeric spirocycle. O-Deprotected compounds 
prepared by the Zemplén method and tested against rabbit muscle glycogen phosphorylase b 
proved to be micromolar inhibitors of the enzyme. Best inhibitors were 1R-1,5-anhydro-D-
glucitol-spiro-[1,5]-2-benzoylimino- (19) and -2-naphthoylimino-1,3-thiazolidin-4-ones (22) 
(Ki 9 and 10 µM, respectively). The corresponding sulfonylimino derivatives (formal 
replacement of the CO group by an SO2 moiety) were much less efficient inhibitors probably 
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due to the tetrahedral geometry of the sulfonyl group. Further extension of the ring system by 
the formation of an annelated cycle gave inactive compounds.  
 
Structural studies of RMGPb in complex with 6, 19, and 22 allowed detailed investigation of 
the binding mode of these compounds at the active site of the enzyme providing interpretation 
of their inhibitory potency assessed by the kinetic experiments. The atoms introduced at the 
spirocycle determine the geometrical features and chemical properties of the inhibitor and act 
as a probe for the adjustments induced in ligand environment upon binding. Taking into 
account previous studies it can be concluded that aromatic moieties such as the 2-naphthyl 
group show a preference for the active site and compounds like 19 and 22 remain attractive 
lead compounds for further optimization using the structure-based drug design approach. 
Further investigation is required for shedding light on the cavity formed above the β-subsite 
and its potential role in promoting in the inactive conformation of the enzyme. 
 
 
4. Experimental 
 
4.1. General methods  
 
Melting points were measured in open capillary tubes or on a Kofler hot-stage and are 
uncorrected. Microwave assisted reactions were carried out in a CEM-Discover Focused 
Microwave Synthesis System (2450 MHz) with a built-in infrared temperature sensor. Optical 
rotations were determined with a Perkin-Elmer 241 polarimeter at room temperature (21-24 
°C). NMR spectra were recorded with Bruker 360 (360/90 MHz for 1H/13C) or Avance DRX 
500 (500/125 MHz for 1H/13C) spectrometers. Chemical shifts are referenced to Me4Si (1H), 
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or to the residual solvent signals (13C). LCMS spectra were recorded by a Thermo Accela 
HPLC & LTQXL mass spectrometer system. TLC was performed on DC-Alurolle Kieselgel 
60 F254 (Merck), and the plates were visualised under UV light and by gentle heating. For 
column chromatography Kieselgel 60 (Merck, particle size 0.063-0.200 mm) was used. 
Organic solutions were dried over anhydrous MgSO4 and concentrated under diminished 
pressure at 40-50 ºC (water bath). Acetone was distilled from KMnO4. DMF, thiourea, acid 
chlorides, and alkyl halides were purchased from Sigma-Aldrich.  
 
4.2. General procedure I for the acylation/sulfonylation of 5 (preparation of 1R-1,5-
anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-acyl(or sulfonyl)imino-1,3-
thiazolidin-4-ones 7-17) 
 
To a solution of 5 (0.20 g, 0.29 mmol) in dry pyridine (3 mL) an acid chloride (3-5 equiv) was 
added. The mixture was then stirred at rt until disappearance of the starting material (TLC, 1:1 
EtOAc-hexane). The solvent was evaporated and the obtained oil was coevaporated with 
toluene (2 x 5 mL), then purified by column chromatography as specified with the particular 
compounds. 
 
4.3. General procedure II for Zemplén-deacylation 
 
To a solution of an O-peracylated compound in dry MeOH 1-2 drops of a ~1 M methanolic 
NaOMe solution were added, and the reaction mixture was kept at rt until completion of the 
transformation (TLC 1:1 CHCl3-MeOH). Amberlyst 15 (H+ form) was then added to remove 
sodium ions, the resin was filtered off, and the solvent was removed. If the residue was 
chromatographically not uniform it was purified by column chromatography or crystallisation.  
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4.4. General procedure III for the alkylation of 5 (preparation of 1R-1,5-anhydro-2,3,4,6-
tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-imino-3-alkyl-1,3-thiazolidin-4-ones 27, 28, 30 and 
1R-1,5-anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-alkylimino-3-alkyl-1,3-
thiazolidin-4-ones 29, 31-33)  
 
To the solution of 5 (0.20 g, 0.29 mmol) in dry DMF (3 mL) containing dry K2CO3 (0.04 g, 
0.29 mmol) a mono- or dihalogen alkane (0.58 mmol) was added. The mixture was stirred at 
rt until the disappearance of the starting material (TLC, 1:1 EtOAc-hexane). It was then 
diluted with water (10 mL) and extracted with EtOAc (5 x 5 mL). The organic layer was 
washed with water (10 mL) and dried. The solvent was removed and the obtained oil was 
purified by column chromatography.  
 
4.5. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-imino-1,3-
thiazolidin-4-one (5)  
 
C-(2,3,4,6-Tetra-O-benzoyl-1-bromo-1-deoxy-β-D-glucopyranosyl)formamide (4, 1.00 g, 
1.42 mmol) was dissolved in dry acetone (10 mL) and thiourea (1.02 g, 17.04 mmol) was 
added in one portion. The mixture was stirred at rt for 11 days, it was then filtered and the 
solvent evaporated. The obtained crude product was purified by column chromatography 
(eluent, 1:1 EtOAc-hexane) to give 0.11 g recovered 4 (conv.: 89 %) and 0.74 g (86 %) of 5 
as an amorphous solid material. Rf=0.21 (1:1 EtOAc-hexane); [α]D +132 (c 0.70, CHCl3); In 
the NMR spectra complete signal assignments are based on COSY, HSQC, and HSQMBC 
correlations. 1H NMR (CDCl3, 500 MHz): δ (ppm) 10.8 (s, 1H, NH), 8.18-7.17 (m, 21H, ArH, 
NH), 6.99 (t, 1H, J3,4  9.2 Hz, H-3), 6.10 (d, 1H, J2,3 9.2 Hz, H-2), 5.92 (pseudo t, 1H, J4,5 10.6 
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Hz, H-4), 5.56 (ddd, 1H, J5,6 3.8 Hz, H-5), 5.20 (dd, 1H, J6,6’ 11.9 Hz, H-6), 4.41 (dd, 1H, J5,6’ 
1.2 Hz, H-6’); 13C NMR (CDCl3, 125 MHz HSQC): δ (ppm) 183.0 (CONH, 3JH-2,CONH= ~5.9 
Hz, HSQMBC), 179.7 (C=N), 166.8, 165.5, 165.3 165.0 (CO), 97.0 (C-1), 73.0 (C-5), 71.9 
(C-3), 70.2 (C-2), 68.8 (C-4), 62.2 (C-6); Anal. Calcd for C36H28N2O10S (680.68): C, 63.52; 
H, 4.15; N, 4.12. Found: C, 63.58; H, 4.05; N, 4.01. 
Alternatively, a solution of 4 (0.10 g, 0.14 mmol) and thiourea (0.84 g, 1.4 mmol) in dry 
EtOH (5 mL) was irradiated by microwaves (100W, 120 oC) for 60 min. The solvent was then 
removed and the residue purified as above to give 18 mg recovered 4 (conv. 82 %) and 0.08 g 
(97 %) of 5. 
 
4.6. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-imino-1,3-thiazolidin-4-one (6) 
 
Prepared from 5 (0.18 g, 0.26 mmol) according to General procedure II and purified by 
column chromatography (eluent, 1:1 CHCl3-MeOH) to give 0.04 g (51%) of 6 as a colourless 
oil. Rf=0.45 (1:1 CHCl3-MeOH); [α]D +16 (c 0.25, H2O); 1H NMR (D2O, 360 MHz): δ (ppm) 
4.32 (ddd, 1H, J5,6 4.0 Hz, H-5), 4.24 (pseudo t, 1H, J3,4  9.2 Hz, H-3), 3.90 (d, 1H, J2,3 9.2 Hz, 
H-2), 3.75 (dd, 1H, J6,6’ 11.9 Hz, Hz, H-6), 3.68 (dd, 1H, J5,6’ 2.6 Hz, H-6’), 3.43 (pseudo t, 
1H, J4,5 10.6 Hz, H-4); 13C NMR (D2O, 90 MHz): δ (ppm) 187.9 (CONH), 181.9 (C=N), 
100.5 (C-1), 77.5, 73.1, 72.9, 69.4 (C-2 - C-5), 61.2 (C-6); Anal. Calcd for C8H12N2O6S 
(264.26): C, 36.36; H, 4.58 N, 10.60. Found: C, 36.26; H, 4.68; N, 10.48. 
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4.7. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-acetylimino-1,3-
thiazolidin-4-one (7)  
 
Prepared from 5 (0.15 g, 0.22 mmol) and AcCl (0.05 mL, 1.10 mmol) according to General 
procedure I. Column chromatography (eluent, 1:1 EtOAc-hexane) gave 0.12 g (76 %) of 7 as 
a yellow powder. Mp: 129-131°C; [α]D +89 (c 0.60, CHCl3); 1H NMR (CDCl3, 360 MHz): δ 
(ppm) 12.60 (s, 1H, NH), 8.05-7.25 (m, 20H, ArH), 6.72 (pseudo t, 1H, J3,4  9.2 Hz, H-3), 
6.14 (d, 1H, J2,3 9.2 Hz, H-2), 5.83 (pseudo t, 1H, J4,5 10.6 Hz, H-4), 5.19 (ddd, 1H, J5,6 1.1 
Hz, H-5), 4.64 (dd, 1H, J6,6’ 11.9 Hz, H-6), 4.49 (dd, 1H, J5,6’ 2.1 Hz, H-6’), 2.47 (s, 3H, 
CH3); 13C NMR (CDCl3, 90 MHz): δ (ppm) 183.9, 182.1, 172.0, 166.0, 165.4, 165.1, 164.5 
(CO, C=N), 133.7-128.2 (ArC), 89.9 (C-1), 71.6, 70.5, 70.1, 68.5 (C-2 - C-5), 62.5 (C-6), 
29.1 (CH3); Anal. Calcd for C38H30N2O11S (722.72): C: 63.15; H: 4.18; N: 3.88; Found: C, 
63.19; H, 4.03; N, 3.75. 
 
4.8. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1.5]-2-(2-methyl-
propanoyl)imino-1,3-thiazolidin-4-one (8) 
 
Prepared from 5 (0.15 g, 0.22 mmol) and (CH3)2CHCOCl (0.12 mL, 1.10 mmol) according to 
General procedure I. Column chromatography (eluent, 1:1 EtOAc-hexane) gave 0.13 g (81 %) 
of 8 as a white powder. Mp: 128-129°C; [α]D +92 (c 0.95, CHCl3); 1H NMR (CDCl3, 360 
MHz): δ (ppm) 12.22 (s, 1H, NH), 8.06-7.24 (m, 20H, ArH), 6.74 (pseudo t, J3,4  9.2 Hz, H-3), 
6.15 (d, 1H, J2,3 9.2 Hz, H-2), 5.85 (pseudo t, 1H, J4,5 10.6 Hz, H-4), 5.23 (ddd, 1H, J5,6 1.2 
Hz, H-5), 4.64 (dd, 1H, J6,6’ 11.9 Hz, H-6), 4.49 (dd, 1H, J5,6’ 2.1 Hz, H-6’), 3.11 (m, 1H, 
CH), 1.22 (d, 3H, J 7.9 Hz, CH3), 1.16 (d, 3H, J 7.9 Hz, CH3); 13C NMR (CDCl3, 90 MHz): δ 
(ppm) 183.6, 182.0, 179.0, 165.9, 165.4, 165.1 164.5 (CO, C=N), 133.6-128.2 (ArC), 89.8 
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(C-1), 71.6, 70.6, 70.2, 68.5 (C-2 - C-5), 62.4 (C-6), 35.6 (CH), 18.8, 18.5 (2 CH3); Anal. 
Calcd for C40H34N2O11S (750.77) : C: 63.99; H: 4.56; N: 3.73; Found: C, 63.89; H, 4.43; N, 
3.65. 
 
4.9. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-pivaloylimino-1,3-
thiazolidin-4-one (9) 
 
Prepared from 5 (0.15 g, 0.22 mmol) and (CH3)3CCOCl (0.14 mL, 1.10 mmol) according to 
General procedure I. Column chromatography (eluent, 1:1 EtOAc-hexane) gave 0.14 g (82 %) 
of 9 as a white powder. Mp: 133-134°C; [α]D +72 (c 1.06, CHCl3); 1H NMR (CDCl3, 360 
MHz): δ (ppm) 10.67 (s, 1H, NH), 8.10-7.22 (m, 20H, ArH), 6.78 (t, 1H, J3,4  9.2 Hz, H-3), 
6.12 (d, 1H, J2,3 9.2 Hz, H-2), 5.92 (t, 1H, J4,5 9.2 Hz, H-4), 5.23 (ddd, 1H, J5,6 1.1 Hz, H-5), 
4.84 (dd, 1H, J6,6’ 11.9 Hz, H-6), 4.42 (dd, 1H, J5,6’ 2.2 Hz, H-6’), 1.18 (s, 9H, C(CH3)3); 13C 
NMR (CDCl3, 90 MHz): δ (ppm) 181.9, 181.6, 177.8, 166.2, 165.2, 165.2, 164.5 (CO, C=N), 
133.6-128.2 (ArC), 95.5 (C(CH3)3), 89.9 (C-1), 71.9, 70.6, 70.5, 68.4 (C-2 - C-5), 62.3 (C-6), 
26.2 (3CH3); Anal. Calcd for C41H36N2O11S (764.80): C: 64.39; H: 4.74; N: 3.66; Found: C, 
64.45; H, 4.68; N, 3.55. 
 
4.10. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-benzoylimino-1,3-
thiazolidin-4-one (10) 
 
Prepared from 5 (0.20 g, 0.29 mmol) and PhCOCl (0.05 m, 0.87 mmol) according to General 
procedure I. Column chromatography (eluent, 1:2 EtOAc-hexane) gave 0.19 g (84 %) of 10 as 
a white powder. Mp: 269-271°C; [α]D +129 (c 0.42, CHCl3); 1H NMR (CDCl3, 360 MHz): δ 
(ppm) 9.88 (s, 1H, NH), 8.14-7.21 (m, 25H, ArH), 6.80 (t, 1H, J3,4  9.2 Hz, H-3), 6.17 (d, 1H, 
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J2,3 9.2 Hz, H-2), 5.93 (pseudo t, 1H, J4,5 10.6 Hz, H-4), 5.33 (ddd, 1H, J5,6 1.2 Hz, H-5), 4.79 
(dd, 1H, J6,6’ 11.9 Hz, H-6), 4.49 (dd, 1H, J5,6’ 3.3 Hz, H-6’); 13C NMR (CDCl3, 90 MHz): δ 
(ppm) 178.1, 171.8,171.3, 166.3, 165.4, 165.1, 164.5 (CO, C=N), 133.9-128.2 (ArC), 88.9 (C-
1), 72.4, 70.8, 70.6, 68.5 (C-2 - C-5), 62.4 (C-6); Anal. Calcd for C43H32N2O11S (784.79): C, 
65.81; H, 4.11; N, 3.57. Found: C, 65.69; H, 4.03; N, 3.45. 
 
4.11. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-4-
methylbenzoylimino-1,3-thiazolidin-4-one (11) 
 
Prepared from 5 (0.30 g, 0.44 mmol) and 4-Me-C6H4COCl (0.30 mL, 2.20 mmol) according 
to General procedure I. Column chromatography (eluent, 1:2 Acetone-hexane) gave 0.19 g 
(53 %) of 11as a yellow oil. Rf=0.88 (2:1 EtOAc-hexane); [α]D +40 (c 0.41, CHCl3); 1H NMR 
(CDCl3, 360 MHz): δ (ppm) 8.62 (s, 1H, NH), 8.02-7.04 (m, 25H, ArH), 6.83 (pseudo t, 1H, 
J3,4  8.0 Hz, H-3), 6.15 (d, 1H, J2,3 9.7 Hz, H-2), 5.93 (t, 1H, J4,5 9.7 Hz, H-4), 5.36 (ddd, 1H, 
J5,6 2.3 Hz, H-5), 4.64 (dd, 1H, J6,6’ 11.7 Hz, H-6), 4.45 (dd, 1H, J5,6’ 3.6 Hz, H-6’), 3.40 (s, 
3H, CH3); 13C NMR (CDCl3, 90 MHz): δ (ppm) 181.6, 176.8, 175.3, 166.2, 165.8, 165.1 
164.6 (CO, C=N), 149.0-123.9 (ArC), 89.7 (C-1), 71.9, 71.1, 70.8, 69.9 (C-2 - C-5), 62.6 (C-
6), 50.2 (CH3); Anal. Calcd for C44H34N2O11S (Mol. Wt.: 798.81, Ex. Mass.: 798.19): C, 
66.16; H, 4.29; N, 3.51. Found: C, 65.99; H, 4.13; N, 3.55; ESI-MS (positive mode) m/z: 
821.182 [M+Na]+. 
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4.12. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-(1-
naphthoylimino)-1,3-thiazolidin-4-one (12) 
 
Prepared from 5 (0.14 g, 0.20 mmol) and 1-naphthoyl chloride (0.10 mL, 0.60 mmol) 
according to General procedure I. Column chromatography (eluent, 1:3 EtOAc-hexane) gave 
0.13 g (73 %) of 13 as a colourless oil. Rf=0.52 (1:1 EtOAc-hexane); [α]D +119 (c 0.25, 
CHCl3); 1H NMR (CDCl3, 360 MHz): δ (ppm) 11.9 (s, 1H, NH), 8.85-7.12 (m, 27H, ArH), 
6.81 (pseudo t, 1H, J3,4  9.2 Hz, H-3), 6.20 (d, 1H, J2,3 10.6 Hz, H-2), 5.94 (pseudo t, 1H, J4,5 
10.6 Hz, H-4), 5.34 (ddd, 1H, J5,6 1.1 Hz, H-5), 4.76 (dd, 1H, J6,6’ 11.9 Hz, H-6), 4.49 (dd, 
1H, J5,6’ 2.6 Hz, H-6’); 13C NMR (CDCl3, 90 MHz): δ (ppm) 178.7, 175.9, 172.3, 166.3, 
165.3, 165.1, 164.6 (CO, C=N), 134.3-124.9 (ArC), 89.2 (C-1), 72.3, 70.7 (2), 68.5 (C-2 - C-
5), 62.4 (C-6); Anal. Calcd for C47H34N2O11S (834.84): C, 67.62; H, 4.10; N, 3.36. Found: C, 
67.68; H, 4.16; N, 3.28. 
 
4.13. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-(2-
naphthoylimino)-1,3-thiazolidin-4-one (13) 
 
Prepared from 5 (0.15 g, 0.22 mmol) and 2-naphthoyl chloride (0.13 g, 0.66 mmol) according 
to General procedure I. Column chromatography (eluent, 1:3 EtOAc-hexane) gave 0.16 g (89 
%) of 12 as a white powder. Mp: 235-236 °C; [α]D +121 (c 0.50, CHCl3); 1H NMR (CDCl3, 
360 MHz): δ (ppm) 10.80 (s, 1H, NH), 8.50-7.33 (m, 27H, ArH), 6.79 (t, 1H, J3,4  9.2 Hz, H-
3), 6.16 (d, 1H, J2,3 9.2 Hz, H-2), 5.93 (pseudo t, 1H, J4,5 10.6 Hz, H-4), 5.30 (ddd, 1H, J5,6 1.1 
Hz, H-5), 4.80 (dd, 1H, J6,6’ 13.2 Hz, H-6), 4.46 (dd, 1H, J5,6’ 2.6 Hz, H-6’); 13C NMR 
(CDCl3, 90 MHz): δ (ppm) 176.3, 176.1, 173.5, 166.2, 165.4, 165.1, 164.5 (CO, C=N), 135.8-
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124.5 (ArC), 88.7 (C-1), 72.4, 70.8, 70.6, 68.5 (C-2 - C-5), 62.4 (C-6); Anal. Calcd for 
C47H34N2O11S (834.84): C, 67.62; H, 4.10; N, 3.36. Found: C, 67.57; H, 4.23; N, 3.30. 
 
4.14. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-
phenylsulfonylimino-1,3-thiazolidin-4-one (14) 
 
Prepared from 5 (0.25 g, 0.37 mmol) and PhSO2Cl (0.28 mL, 1.85 mmol) according to 
General procedure I. Column chromatography (eluent, 1:1 Acetone-hexane) gave 0.14 g (55 
%) of 14 as a yellowish oil. Rf=0.21 (2:1 EtOAc-hexane); [α]D +48 (c 0.39, CHCl3); 1H NMR 
(CDCl3, 360 MHz): δ (ppm) 9.18 (s, 1H, NH), 8.04-7.14 (m, 25H, ArH), 6.72 (pseudo t, 1H, 
J3,4  9.3 Hz, H-3), 6.06 (d, 1H, J2,3 9.7 Hz, H-2), 5.86 (t, 1H, J4,5 9.7 Hz, H-4), 5.32 (ddd, 1H, 
J5,6 1.2 Hz, H-5), 4.59 (dd, 1H, J6,6’ 11.7 Hz, H-6), 4.43 (dd, 1H, J5,6’ 3.1 Hz, H-6’); 13C NMR 
(CDCl3, 90 MHz): δ (ppm) 180.6, 169.6, 166.1, 165.5, 165.0, 164.5 (CO, C=N), 138.8-124.7 
(ArC), 88.5 (C-1), 72.6, 71.1, 70.8, 68.5 (C-2 - C-5), 62.3 (C-6); Anal. Calcd for 
C42H32N2O12S2 (Mol. Wt.: 820.84, Ex. Mass.: 820.14): C, 61.46; H, 3.93; N, 3.41. Found: C, 
61.56; H, 4.03; N, 3.21; ESI-MS (positive mode) m/z: 843.131 [M+Na]+. 
 
4.15. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-(4-
methylphenylsulfonylimino)-1,3-thiazolidin-4-one (15) 
 
Prepared from 5 (0.15 g, 0.23 mmol) and 4-Me-C6H4SO2Cl (0.17 g, 1.04 mmol) according to 
General procedure I. Column chromatography (eluent, 5:1 EtOAc-hexane) gave 0.14 g (70 %) 
of 15 as a yellowish crystalline product from hexane. Mp: 161-164 °C; [α]D +88 (c 0.42, 
CHCl3); 1H NMR (CDCl3, 360 MHz): δ (ppm) 7.99-7.10 (m, 24H, ArH), 6.80 (t, 1H, J3,4  9.2 
Hz, H-3), 6.00 (d, 1H, J2,3 9.2 Hz, H-2), 5.77 (pseudo t, 1H, J4,5 10.6 Hz, H-4), 5.30 (ddd, 1H, 
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J5,6’ 2.1 Hz, J5,6 1.1 Hz, H-5), 4.38-4.32 (m, 2H, H-6, H-6’), 2.10 (s, 3H, CH3); 13C NMR 
(CDCl3, 90 MHz): δ (ppm) 178.3, 170.6, 166.0, 165.9, 165.3, 164.7 (CO, C=N), 139.2-126.6 
(ArC), 88.7 (C-1), 72.3, 71.0 (2), 68.6 (C-2 - C-5), 62.3 (C-6), 21.4 (CH3); Anal. Calcd for 
C43H34N2O12S2 (Mol. Wt.: 834.86, Ex. Mass.: 834.16): C, 61.86; H, 4.10; N, 3.36. Found: C, 
61.76; H, 4.13; N, 3.31; ESI-MS (positive mode) m/z: 857.142 [M+Na]+. 
 
4.16. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-(1-
naphthylsulfonylimino)-1,3-thiazolidin-4-one (16) 
 
Prepared from 5 (0.24 g, 0.35 mmol) and 1-naphthylsulfonyl chloride (0.40 g, 1.75 mmol) 
according to General procedure I. Column chromatography (eluent, 2:1 EtOAc-hexane) gave 
0.14 g (45 %) of 16 as a yellowish oil. Rf=0.30 (2:1 EtOAc-hexane); [α]D +65 (c 0.35, 
CHCl3); 1H NMR (CDCl3, 360 MHz): δ (ppm) 9.94 (s, 1H, NH), 8.48-7.12 (m, 27H, ArH), 
6.57 (t, 1H, J3,4  9.7 Hz, H-3), 6.02 (d, 1H, J2,3 9.7 Hz, H-2), 5.87 (t, 1H, J4,5 9.7 Hz, H-4), 
5.15 (ddd, 1H, J5,6 1.5 Hz, H-5), 4.62 (dd, 1H, J6,6’ 12.3 Hz, H-6), 4.42 (dd, 1H, J5,6’ 3.1 Hz, 
H-6’); 13C NMR (CDCl3, 90 MHz): δ (ppm) 183.6, 169.9, 166.1, 165.2, 165.0, 164.3 (CO, 
C=N), 134.7-123.9 (ArC), 88.4 (C-1), 73.3, 70.9, 70.6, 68.1 (C-2 - C-5), 62.2 (C-6); Anal. 
Calcd for C46H34N2O12S2 (Mol. Wt.: 870.90, Ex. Mass.: 870.16): C, 63.44; H, 3.94; N, 3.22. 
Found: C, 63.59; H, 4.01; N, 3.38; ESI-MS (positive mode) m/z: 893.141 [M+Na]+. 
 
4.17. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-(2-
naphthylsulfonylimino)-1,3-thiazolidin-4-one (17) 
 
Prepared from 5 (0.24 g, 0.35 mmol) and 2-naphthylsulfonyl chloride (0.40 g, 1.75 mmol) 
according to General procedure I. Column chromatography (eluent, 2:1 EtOAc-hexane) gave 
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0.19 g (62 %) of 17 as a yellowish oil. Rf=0.17 (2:1 EtOAc-hexane); [α]D +40 (c 0.43, 
CHCl3); 1H NMR (CDCl3, 360 MHz): δ (ppm) 8.36-7.28 (m, 27H, ArH), 6.57 (t, 1H, J3,4  9.7 
Hz, H-3), 6.03 (d, 1H, J2,3 9.7 Hz, H-2), 5.88 (t, 1H, J4,5 9.7 Hz, H-4), 5.22 (ddd, 1H, J5,6 2.5 
Hz, H-5), 4.65 (dd, 1H, J6,6’ 12.3 Hz, H-6), 4.46 (dd, 1H, J5,6’ 3.7 Hz, H-6’); 13C NMR 
(CDCl3, 90 MHz): δ (ppm) 180.2, 170.3, 166.1, 165.3, 165.0, 164.3 (CO, C=N), 135.7-121.8 
(ArC), 88.4 (C-1), 73.4, 71.2, 70.5, 68.2 (C-2 - C-5), 62.3 (C-6); Anal. Calcd for 
C46H34N2O12S2 (Mol. Wt.: 870.90, Ex. Mass.: 870.16): C, 63.44; H, 3.94; N, 3.22. Found: C, 
63.56; H, 3.84; N, 3.33; ESI-MS (positive mode) m/z: 893.141 [M+Na]+. 
 
4.18. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-pivaloylimino-1,3-thiazolidin-4-one (18) 
 
Prepared from 9 (0.13 g, 0.17 mmol) according to General procedure II and purified by 
column chromatography (eluent, 9:1 CHCl3-MeOH) to give 0.02 g (26%) of 18 as a yellow 
oil. Rf=0.17 (9:1 CHCl3-MeOH); [α]D -69 (c 0.05, MeOH); 1H NMR (CD3OD, 360 MHz): δ 
(ppm) 4.36 (ddd, 1H, J5,6 4.0 Hz, H-5), 4.23 (t, 1H, J3,4  9.2 Hz, H-3), 3.84 (dd, 1H, J5,6’ 2.6 
Hz, H-6’), 3.72 (d, 1H, J2,3 9.2 Hz, H-2), 3.69 (dd, 1H, J6,6’ 11.9 Hz, H-6), 3.40 (t, 1H, J4,5 9.2 
Hz, H-4); 13C NMR (CD3OD, 90 MHz): δ (ppm) 185.6, 178.9, 165.9 (CO, C=N), 94.9 (C-1), 
86.0 (C(CH3)3) 78.4, 75.0, 74.2, 70.8 (C-2 - C-5), 62.7 (C-6), 27.1 (CH3); Anal. Calcd for 
C13H20N2O7S (348.38): C, 44.82; H, 5.79; N, 8.04. Found: C, 44.75; H, 5.72; N, 8.08. 
 
4.19. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-benzoylimino-1,3-thiazolidin-4-one (19) 
 
Prepared from 10 (0.13 g, 0.16 mmol) according to General procedure II and purified by 
column chromatography (eluent, 4:1 CHCl3-MeOH) and then crystallised from water to give 
0.04 g (55 %) of 19 as a white solid. Mp: 242-244°C; [α]D +27 (c 0.20, H2O); 1H NMR (D2O, 
  
34 
 
360 MHz): δ (ppm) 7.94-7.89 (m, 2H, ArH), 7.50-7.43 (m, 3H, ArH), 4.35 (ddd, 1H, J5,6 2.1 
Hz, H-5), 4.25 (t, 1H, J3,4  9.2 Hz, H-3), 3.94 (d, 1H, J2,3 9.2 Hz, H-2), 3.85 (dd, 1H, J6,6’ 11.9 
Hz, H-6), 3.74 (dd, 1H, J5,6’ 4.0 Hz, H-6’) 3.52 (t, 1H, J4,5 9.2 Hz, H-4); 13C NMR (D2O, 90 
MHz): δ (ppm) 177.2, 175.4, 170.5 (CO, C=N), 132.7-129.0 (ArC), 92.3 (C-1), 76.9, 73.0, 
72.8, 69.2 (C-2 - C-5), 61.1 (C-6); Anal. Calcd for C15H16N2O7S (368.36): C, 48.91; H, 4.38; 
N, 7.60. Found: C, 48.87; H, 4.43; N, 7.55. 
 
4.20. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-(4-methylbenzoylimino)-1,3-thiazolidin-4-
one (20) 
 
Prepared from 11 (0.19 g, 0.23 mmol) according to General procedure II and purified by 
column chromatography (eluent, 7:3 CHCl3-MeOH) to give 0.04 g (43 %) of 20 as a white 
crystalline product. Mp: 149-152°C; [α]D +52 (c 0.37, H2O); 1H NMR (CD3OD, 360 MHz): δ 
(ppm) 8.03 (d, 2H, J 8.0 Hz, ArH), 7.23 (d, 1H, J 8.0 Hz, ArH), 4.34 (ddd, 1H, J5,6 1.1 Hz, H-
5), 4.20 (t, 1H, J3,4  9.3 Hz, H-3), 3.80 (dd, 1H, J6,6’ 12.3 Hz, H-6), 3.66 (d, 1H, J2,3 9.3 Hz, H-
2), 3.63 (dd, 1H, J5,6’ 4.9 Hz, H-6’) 3.35 (t, 1H, J4,5 9.3 Hz, H-4), 2.35 (s, 1H, CH3); 13C NMR 
(CD3OD, 90 MHz): δ (ppm) 181.0, 179.1, 176.5 (CO, C=N), 145.2-130.1 (ArC), 92.9 (C-1), 
78.3, 75.2, 74.3, 70.9 (C-2 - C-5), 62.8 (C-6), 21.7 (CH3); Anal. Calcd for C16H18N2O7S (Mol. 
Wt.: 382.39, Ex. Mass.: 382.08): C, 50.26; H, 4.74; N, 7.33. Found: C, 50.37; H, 4.63; N, 
7.45; ESI-MS (positive mode) m/z: 405.075 [M+Na]+. 
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4.21. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-(1-naphthoylimino)-1,3-thiazolidin-4-one 
(21) 
 
Prepared from 12 (0.10 g, 0.12 mmol) according to General procedure II and purified by 
column chromatography (eluent, 4:1 CHCl3-MeOH) to give 0.03 g (56 %) of 21 as a 
colourless oil. Rf=0.59 (7:3 CHCl3-MeOH); [α]D +38 (c 0.20, DMSO); 1H NMR (D2O, 360 
MHz): δ (ppm) 8.31-7.27 (m, 7H ArH), 4.31 (ddd, 1H, J5,6 1.0 Hz, H-5), 4.22 (t, 1H, J3,4  9.2 
Hz, H-3), 3.88 (d, 1H, J2,3 9.2 Hz, H-2), 3.77 (dd, 1H, J6,6’ 11.9 Hz, H-6), 3.67 (dd, 1H, J5,6’ 
2.6 Hz, H-6’) 3.45 (pseudo t, 1H, J4,5 10.6 Hz, H-4); 13C NMR (D2O, 90 MHz): δ (ppm) 
182.3, 177.9, 175.4 (CO, C=N), 134.6-125.1 (ArC), 92.9 (C-1), 77.0, 73.3, 73.1, 69.5 (C-2 - 
C-5), 61.4 (C-6); Anal. Calcd for C19H18N2O7S (418.42): C, 54.54; H, 4.34; N, 6.70. Found: 
C, 54.48; H, 4.39; N, 6.67. 
 
4.22. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-(2-naphthoylimino)-1,3-thiazolidin-4-one 
(22) 
 
Prepared from 13 (0.14 g, 0.16 mmol) according to General procedure II and purified by 
column chromatography (eluent, 4:1 CHCl3-MeOH) to give 0.04 g (50 %) of 22 as an 
amorphous white material. Rf=0.45 (4:1 CHCl3-MeOH); [α]D +35 (c 1.06, DMSO); 1H NMR 
(DMSO-d6, 360 MHz): δ (ppm) 8.78 (s, 1H, NH), 8.20-7.60 (m, 7H, ArH), 6.05, 5.14, 4.56 
(3s, 3H, OH), 4.18 (dd, 1H, J 5.3 Hz, J 5.2 Hz, OH) , 4.15 (ddd, 1H, J5,6 1.0 Hz, H-5), 3.95 (t, 
1H, J3,4  9.2 Hz, H-3), 3.65 (dd, 1H, J6,6’ 11.9 Hz, H-6), 3.54 (d, 1H, J2,3 9.2 Hz, H-2), 3.42 
(dd, 1H, J5,6’ 4.0 Hz, H-6’) 3.16 (t, 1H, J4,5 9.2 Hz, H-4); 13C NMR (DMSO-d6, 90 MHz): δ 
(ppm) 186.9, 176.3 (2) (CO, C=N), 135.0-125.1 (ArC), 90.9 (C-1), 77.5, 73.6, 72.4, 69.1 (C-2 
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- C-5), 61.1 (C-6); Anal. Calcd for C19H18N2O7S (418.42): C, 54.54; H, 4.34; N, 6.70. Found: 
C, 54.44; H, 4.43; N, 6.75. 
 
4.23. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-phenylsulfonylimino-1,3-thiazolidin-4-one 
(23) 
 
Prepared from 14 (0.16 g, 0.19 mmol) according to General procedure II and purified by 
column chromatography (eluent, 7:1 CHCl3-MeOH) to give 0.08 g (98 %) of 23 as a white 
crystalline product. Mp: 156-159 °C; [α]D +82 (c 0.41, H2O); 1H NMR (CD3OD, 360 MHz): 
δ (ppm) 7.93-7.90 (m, 2H, ArH), 7.56-7.47 (m, 3H, ArH), 4.35 (ddd, 1H, J5,6 1.4 Hz, H-5), 
4.28 (t, 1H, J3,4  9.3 Hz, H-3), 3.75 (dd, 1H, J6,6’ 12.1 Hz, H-6), 3.70 (d, 1H, J2,3 9.3 Hz, H-2), 
3.62 (dd, 1H, J5,6’ 4.9 Hz, H-6’), 3.34 (t, 1H, J4,5 9.3 Hz, H-4); 13C NMR (CD3OD, 90 MHz): 
δ (ppm) 182.0, 173.8 (CO, C=N), 143.8-127.8 (ArC), 98.1 (C-1), 77.8, 74.9, 74.3, 71.0 (C-2 - 
C-5), 62.8 (C-6); Anal. Calcd for C14H16N2O8S2 (Mol. Wt.: 404.42, Ex. Mass.: 404.03): C, 
41.58; H, 3.99; N, 6.93. Found: C, 41.65; H, 3.89; N, 7.05; ESI-MS (positive mode) m/z: 
427.026 [M+Na]+. 
 
4.24. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-(4-methylphenylsulfonylimino)-1,3-
thiazolidin-4-one (24) 
 
Prepared from 15 (0.16 g, 0.19 mmol) according to General procedure II and purified by 
column chromatography (eluent, 4:1 CHCl3-MeOH) to give 0.08 g (97 %) of 24 as a 
colourless oil. Rf=0.32 (7:3 CHCl3-MeOH); [α]D +39 (c 0.20, MeOH); 1H NMR (CD3OD, 
360 MHz): δ (ppm) 7.78 (d, 2H, J 7.9 Hz, ArH), 7.35 (d, 2H, J 7.9 Hz, ArH), 4.29 (ddd, 1H, 
J5,6 2.1 Hz, H-5), 4.18 (t, 1H, J3,4  9.2 Hz, H-3), 3.79 (d, 1H, J2,3 9.2 Hz, H-2), 3.69 (dd, 1H, 
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J6,6’ 11.9 Hz, H-6), 3.66 (dd, 1H, J5,6’ 4.0 Hz, H-6’), 3.37 (t, 1H, J4,5 9.2 Hz, H-4), 2.42 (s, 3H, 
CH3); 13C NMR (CD3OD, 90 MHz): δ (ppm) 179.4, 173.7 (CO, C=N), 145.2-127.9 (ArC), 
94.9 (C-1), 78.9, 75.0, 74.4, 70.6 (C-2 - C-5), 62.6 (C-6), 21.5 (CH3); Anal. Calcd for 
C15H18N2O8S2 (Mol. Wt.: 418.44, Ex. Mass: 418.05): C, 43.36; H, 4.34; N, 6.69. Found: C, 
43.26; H, 4.43; N, 6.55; ESI-MS (positive mode) m/z: 441.042 [M+Na]+. 
 
4.25. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-(1-naphthylsulfonylimino)-1,3-thiazolidin-
4-one (25) 
 
Prepared from 16 (0.13 g, 0.14 mmol) according to General procedure II and purified by 
column chromatography (eluent, 7:3 CHCl3-MeOH) to give 0.06 g (96 %) of 25 as a white 
crystalline product. Mp: 169-172 °C; [α]D +71 (c 0.49, H2O); 1H NMR (CD3OD, 360 MHz): 
δ (ppm) 8.69-7.56 (m, 7H, ArH), 4.26 (ddd, 1H, J5,6 1.8 Hz, H-5), 4.16 (t, 1H, J3,4  9.2 Hz, H-
3), 3.80 (dd, 1H, J6,6’ 11.7 Hz, H-6), 3.71 (d, 1H, J2,3 9.2 Hz, H-2), 3.64 (dd, 1H, J5,6’ 5.5 Hz, 
H-6’), 3.37 (t, 1H, J4,5 9.2 Hz, H-4); 13C NMR (CD3OD, 90 MHz): δ (ppm) 178.4, 171.2 (CO, 
C=N), 137.2-125.3 (ArC), 94.2 (C-1), 79.1, 75.1, 74.4, 70.5 (C-2 - C-5), 62.6 (C-6); Anal. 
Calcd for C18H18N2O8S2 (Mol. Wt.: 454.47, Ex. Mass: 454.05): C, 47.57; H, 3.99; N, 6.16. 
Found: C, 47.53; H, 4.11; N, 6.32; ESI-MS (positive mode) m/z: 477.043 [M+Na]+. 
 
4.26. 1R-1,5-Anhydro-D-glucitol-spiro-[1,5]-2-(2-naphthylsulfonylimino)-1,3-thiazolidin-
4-one (26) 
 
Prepared from 17 (0.19 g, 0.21 mmol) according to General procedure II and purified by 
column chromatography (eluent, 7:3 CHCl3-MeOH) to give 0.10 g (98 %) of 26 as a white 
crystalline product. Mp: 168-171 °C; [α]D +68 (c 0.35, H2O); 1H NMR (CD3OD, 360 MHz): 
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δ (ppm) 8.47-7.58 (m, 7H, ArH), 4.34 (ddd, 1H, J5,6 2.1 Hz, H-5), 4.26 (pseudo t, 1H, J3,4  9.1 
Hz, H-3), 3.74 (dd, 1H, J6,6’ 11.7 Hz, H-6), 3.69 (d, 1H, J2,3 9.3 Hz, H-2), 3.60 (dd, 1H, J5,6’ 
4.9 Hz, H-6’), 3.42 (pseudo t, 1H, J4,5 9.3 Hz, H-4); 13C NMR (CD3OD, 90 MHz): δ (ppm) 
182.1, 174.6 (CO, C=N), 140.7-123.9 (ArC), 98.2 (C-1), 77.8, 74.9, 74.3, 71.0 (C-2 - C-5), 
62.8 (C-6); Anal. Calcd for C18H18N2O8S2 (Mol. Wt.: 454.47, Ex. Mass: 454.05): C, 47.57; H, 
3.99; N, 6.16. Found: C, 47.66; H, 3.87; N, 6.25; ESI-MS (positive mode) m/z: 477.043 
[M+Na]+. 
 
4.27. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-imino-3-methyl-1,3-
thiazolidin-4-one (27)  
 
Prepared from 5 (0.30 g, 0.44 mmol) and CH3I (0.01 mL, 0.88 mmol) according to General 
procedure III. Column chromatography (eluent, 1:2 EtOAc-hexane) gave 0.1 g (62 %) of 27 
as a colourless oil. Rf=0.62 (1:2 EtOAc-hexane); [α]D +97 (c 0.20, CHCl3); 1H NMR (CDCl3, 
360 MHz): δ (ppm) 8.07-7.25 (m, 21H, ArH, NH), 6.69 (pseudo t, 1H, J3,4  9.2 Hz, H-3), 5.96 
(d, 1H, J2,3 10.6 Hz, H-2), 5.85 (pseudo t, 1H, J4,5  9.2 Hz, H-4), 5.20 (ddd, 1H, J5,6 2.6 Hz, H-
5), 4.65 (dd, 1H, J6,6’13.2 Hz, H-6), 4.35 (dd, 1H, J5,6’ 3.9 Hz, H-6’), 3.30 (s, 3H, CH3); 13C 
NMR (CDCl3, 90 MHz): δ (ppm) 169.8, 166.0, 165.3, 165.0, 164.7, 155.8 (CO, C=N), 133.8-
128.1 (ArC), 90.8 (C-1), 73.7, 71.5, 71.1, 68.5 (C-2 - C-5), 62.4 (C-6), 28.4 (CH3); Anal. 
Calcd for C37H30N2O10S (694.71) Számított: C: 63.97, H: 4.35, N: 4.03. Found: C, 63.88; H, 
4.41; N, 4.00. 
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4.28. Allylation of 5 to 1R-1,5-anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-
imino-3-allyl-1,3-thiazolidin-4-one (28) and 1R-1,5-anhydro-2,3,4,6-tetra-O-benzoyl-D-
glucitol-spiro-[1,5]-2-allylimino-3-allyl-1,3-thiazolidin-4-one (29) 
 
Prepared from 5 (0.10 g, 0.15 mmol) and CH2CHCH2Br (0.03 mL, 0.30 mmol) according to 
General procedure III. Column chromatography (eluent, 1:2 EtOAc-hexane) gave as the first 
fraction 0.025 g (25 %) of 28 as a colourless oil. Rf=0.37 (1:2 EtOAc-hexane); [α]D +119 (c 
0.28, CHCl3); 1H NMR (CDCl3, 360 MHz): δ (ppm) 8.06-7.26 (m, 21H, ArH, NH), 6.70 
(pseudo t, 1H, J3,4  9.2 Hz, H-3), 5.96 (d, 1H, J2,3 10.6 Hz, H-2), 5.85-5.80 (m, 2H, CH, H-4), 
5.25 (dd, 2H, J 15 Hz, J 9.2 Hz, CH2), 5.16 (ddd, 1H, J4,5 9.2 Hz, J5,6’ 2.1 Hz, J5,6 1.1 Hz, H-
5), 4.64 (dd, 1H, J6,6’13.2 Hz, H-6), 4.44-4.42 (m, 3H, H-6’, CH2); 13C NMR (CDCl3, 90 
MHz): δ (ppm) 169.1, 166.0, 165.2, 165.1, 164.9, 155.2 (CO,C=N), 133.4-128.2 (ArC, CH), 
111.8 (CH2), 90.6 (C-1), 73.6, 71.2, 71.1, 68.5 (C-2 - C-5), 62.5 (C-6), 43.9 (CH2); Anal. 
Calcd for C39H32N2O10S (720.74) C: 64.99, H: 4.48, N: 3.89. Found: C, 64.89; H, 4.43; N, 
3.67. 
The second fraction contained 0.30 g (26 %) of 29 as a colourless oil, Rf=0.17 (1:2 EtOAc-
hexane); [α]D +33 (c 0.12, CHCl3);  1H NMR (CDCl3, 360 MHz): δ (ppm) 8.08-7.25 (m, 20H, 
ArH), 6.79 (pseudo t, 1H, J3,4  9.2 Hz, H-3), 6.10 (d, 1H, J2,3 10.6 Hz, H-2), 5.85 (pseudo t, 
1H, J4,5  9.2 Hz, H-4), 5.62 (m, 1H, CH), 5.54-5.43 (m, 2H, CH, H-5), 5.10 (dd, 2H, J 15 Hz, 
J 6.6 Hz, CH2), 4.98 (dd, 2H, J 15 Hz, J 6.6 Hz, CH2), 4.60 (dd, 1H, J6,6’13.2 Hz, J5,6 4.0 Hz, 
H-6), 4.43 (dd, 1H, J5,6’ 2.6 Hz, H-6’), 3.88-3.76 (m, 4H, 2 x CH2); 13C NMR (CDCl3, 90 
MHz): δ (ppm) 183.9, 177.8, 165.1, 165.0 (2), 164.9 (CO, C=N), 133.6-128.2 (ArC, 2 x CH), 
119.7, 119.5 (2 x CH2), 97.9 (C-1), 72.1, 71.3, 70.9, 68.7 (C-2 - C-5), 62.7 (C-6), 52.6, 52.2 
(2 x CH2); Anal. Calcd for C42H36N2O10S  (760.81) C: 66.33, H: 4.77, N: 3.68. Found: C, 
66.29; H, 4.63; N, 3.61. 
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4.29. Benzylation of 5 to 1R-1,5-anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,5]-2-
imino-3-benzyl-1,3-thiazolidin-4-one (30) and 1R-1,5-anhydro-2,3,4,6-tetra-O-benzoyl-D-
glucitol-spiro-[1,5]-2-benzylimino-3-benzyl-1,3-thiazolidin-4-one (31) 
 
Prepared from 5 (0.30 g, 0.44 mmol) and PhCH2Br (0.16 mL, 1.32 mmol) according to 
General procedure III. Column chromatography (eluent, 1:3 EtOAc-hexane) gave as the first 
fraction 0.12 g (34 %) of 30 as a colourless oil. Rf=0.12 (1:3 EtOAc-hexane); [α]D +104 (c 
0.35, CHCl3); 1H NMR (CDCl3, 360 MHz): δ (ppm) 8.10-7.23 (m, 26H, ArH, NH), 6.74 
(pseudo t, 1H, J3,4  9.2 Hz, H-3), 5.99 (d, 1H, J2,3 9.2 Hz, H-2), 5.85 (pseudo t, 1H, J4,5 10.6 
Hz, H-4), 5.18 (ddd, 1H, J5,6 2.6 Hz, H-5), 5.03-5.01 (m, 2H, CH2), 4.63 (dd, 1H, J6,6’13.2 Hz, 
H-6), 4.66 (dd, 1H, J5,6’ 4.0 Hz, H-6’); 13C NMR (CDCl3, 90 MHz): δ (ppm) 169.5, 166.0, 
165.2, 165.0, 164.7, 154.8 (CO, C=N), 135.2-127.8 (ArC), 90.5 (C-1), 73.5, 71.2, 71.0, 68.5 
(C-2 - C-5), 62.5 (C-6), 45.2 (CH2); Anal. Calcd for C43H34N2O10S (770.80): C, 67.00; H, 
4.45; N, 3.63. Found: C, 66.95; H, 4.37; N, 3.68. 
The second fraction gave 0.06 g (16 %) of 31 as a colourless oil Rf=0.07 (1:3 EtOAc-hexane); 
[α]D +139 (c 0.30, CHCl3); 1H NMR (CDCl3, 360 MHz): δ (ppm) 8.10-6.90 (m, 30H, ArH), 
6.85 (pseudo t, 1H, J3,4  9.2 Hz, H-3), 6.18 (d, 1H, J2,3 10.6 Hz, H-2), 5.89 (pseudo t, 1H, J4,5 
10.6 Hz, H-4), 5.54 (ddd, 1H, J5,6 2.6 Hz, H-5), 4.93 (d, 1H, J 14.5 Hz,CH2), 4.69-4.63 (m, 
2H, CH2, H-6), 4.45 (dd, 1H, J6,6’13.2 Hz, J5,6’ 4.0 Hz, H-6’), 4.30-4.28 (m, 2H, CH2); 13C 
NMR (CDCl3, 90 MHz): δ (ppm) 184.2, 178.7, 166.1, 165.2 (2), 164.8 (CO, C=N), 135.2-
127.8 (ArC), 98.1 (C-1), 72.2, 71.2, 71.0, 68.7(C-2 - C-5), 62.6 (C-6), 52.9, 52.5 (2 x CH2); 
Anal. Calcd for C50H40N2O10S (860.92): C, 69.75; H, 4.68; N, 3.25. Found: C, 69.71; H, 4.62; 
N, 3.30. 
 
  
41 
 
4.30. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,2]-(5,6-dihydro-
imidazo[2,1-b]thiazolidin-3-one) (32) 
 
Prepared from 5 (0.20 g, 0.29 mmol) and Br(CH2)2Br (0.075 mL, 0.87 mmol) according  to 
General procedure III. Column chromatography (eluent, 1:1 EtOAc-hexane) gave 0.14 g (67 
%) of 32 as white crystals. Mp: 202-205 °C; [α]D +195 (c 0.55, CHCl3); 1H NMR (CDCl3, 
360 MHz): δ (ppm) 8.07-7.23 (m, 20H, ArH), 6.67 (pseudo t, 1H, J3,4  9.2 Hz, H-3), 5.98 (d, 
1H, J2,3 10.6 Hz, H-2), 5.85 (pseudo t, 1H, J4,5 10.6 Hz, H-4), 5.20 (ddd, 1H, J5,6 4.0 Hz, H-5), 
4.66 (dd, 1H, J5,6’ 2.6 Hz, H-6’), 4.66 (dd, 1H, J6,6’13.2 Hz, H-6), 4.32-4.24 (m, 1H, CH2), 
4.21-4.13 (m, 1H, CH2), 3.88-3.74 (m, 2H, CH2); 13C NMR (CDCl3, 90 MHz): δ (ppm) 166.0, 
165.2, 165.0, 164.5 163.3, 156.1 (CO, C=N), 133.7-128.5 (ArC), 97.6 (C-1), 73.8, 72.0, 70.9, 
68.4 (C-2 - C-5), 62.4 (C-6), 60.5, 41.7 (2 x CH2); Anal. Calcd for C38H30N2O10S (706.72): C, 
64.58; H, 4.28; N, 3.96. Found: C, 64.49; H, 4.33; N, 3.88. 
 
4.31. 1R-1,5-Anhydro-2,3,4,6-tetra-O-benzoyl-D-glucitol-spiro-[1,2]-(6,7-dihydro-5H-
thiazolidino[3,2-a]pyrimidin-3-one) (33) 
 
Prepared from 5 (0.20 g, 0.29 mmol) and Br(CH2)3Br (0.09 mL, 0.87 mmol) according to 
General procedure III. Column chromatography (eluent, 1:1 EtOAc-hexane) gave 0.15 g (70 
%) of 33 as a white crystals. Mp: 234-236 °C; [α]D +181 (c 0.42, CHCl3); 1H NMR (CDCl3, 
360 MHz): δ (ppm) 8.05-7.24 (m, 20H, ArH), 6.69 (t, 1H, J3,4  9.2 Hz, H-3), 6.00 (d, 1H, J2,3 
9.2 Hz, H-2), 5.87 (t, 1H, J4,5 9.2 Hz, H-4), 5.20 (ddd, 1H, J5,6 2.3 Hz, H-5), 4.66 (dd, 1H, 
J6,6’13.2 Hz, H-6), 4.66 (dd, 1H, J5,6’ 1.1 Hz, H-6’), 3.83-3.81 (m, 1H, CH2), 3.72-3.68 (m, 
1H, CH2), 3.48-3.42 (m, 2H, CH2), 1.90-1.87 (m, 1H, CH2), 1.73-1.70 (m, 1H, CH2); 13C 
NMR (CDCl3, 90 MHz): δ (ppm) 166.0, 165.9, 165.3, 164.9, 164.3, 147.5 (CO, C=N), 133.6-
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128.3 (ArC), 88.3 (C-1), 73.4, 71.5, 70.0, 68.5 (C-2 - C-5), 62.4 (C-6), 46.2, 40.6, 19.2 (3 x 
CH2); Anal. Calcd for C39H32N2O10S (720.74): C, 64.99; H, 4.48; N, 3.89. Found: C, 64.89; 
H, 4.38; N, 3.80. 
 
4.32. 1R-1,5-Anhydro-D-glucitol-spiro-[1,2]-(5,6-dihydro-imidazo[2,1-b]thiazolidin-3-
one) (34) 
 
Prepared from 32 0.14 g (0.20 mmol) according to General procedure II and purified by 
column chromatography (eluent, 7:3 CHCl3-MeOH) to give 0.025 g (43 %) of 34 as a pale 
yellowish oil. Rf=0.36 (7:3 CHCl3-MeOH); [α]D +103 (c 0.20, MeOH); 1H NMR (CD3OD, 
360 MHz): δ (ppm) 4.36-4.24 (m, 4H, H-5, H-6, CH2), 4.17 (t, 1H, J2,3 9.2 Hz, J3,4  9.2 Hz, H-
3), 3.86-3.74 (m, 2H, H-2, H-6’), 3.69-3.63 (m, 2H, CH2), 3.38 (t, 1H, J4,5 9.2 Hz, H-4); 13C 
NMR (CD3OD, 90 MHz): δ (ppm) 166.9, 160.9 (CO, C=N), 102.7 (C-1), 80.0, 76.4, 74.6, 
70.6 (C-2 - C-5), 62.6 (C-6), 60.8, 42.5 (2 x CH2); Anal. Calcd for C10H14N2O6S (290.29): C, 
41.37 H, 4.86; N, 9.65. Found: C, 41.28; H, 4.77; N, 9.60. 
 
4.33. 1R-1,5-Anhydro-D-glucitol-spiro-[1,2]-(6,7-dihydro-5H-thiazolidino[3,2-
a]pyrimidin-3-one) (35) 
 
Prepared from 33 (0.15 g, 0.20 mmol) according to General procedure II and purified by 
column chromatography (eluent, 7:3 CHCl3-MeOH) to give 0.03 g (48 %) of 35 as a 
colourless oil.  Rf=0.40 (7:3 CHCl3-MeOH); [α]D +106 (c 0.20, MeOH); 1H NMR (CD3OD, 
360 MHz): δ (ppm) 4.26 (ddd, 1H, J5,6 4.0 Hz, J5,6’2.1 Hz, H-5), 4.18 (t, 1H, J2,3 9.2 Hz, J3,4  
9.2 Hz, H-3), 3.80 (dd, 1H, J6,6’11.9 Hz, H-6), 3.69-3.61 (m, 4H, H-2, H-6’, CH2), 3.54-3.47 
(m, 2H, CH2), 3.36 (t, 1H, J4,5 9.2 Hz, H-4), 3.34-3.30 (m, 2H, CH2); 13C NMR (CD3OD, 90 
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MHz): δ (ppm) 171.3, 153.6 (CO, C=N), 92.7 (C-1), 79.6, 75.7, 74.7, 70.7 (C-2 - C-5), 62.7 
(C-6), 47.0, 41.5, 20.4 (3 x CH2); Anal. Calcd for C11H16N2O6S (304.32): C, 43.41 H, 5.30; N, 
9.21. Found: C, 43.33; H, 5.37; N, 9.29. 
 
4.34. Enzyme preparation 
 
RMGPb was isolated from rabbit skeletal muscle and purified as described previously.48 
Kinetic studies were performed in the direction of glycogen synthesis in the presence of 
various concentrations of the inhibitors. Enzyme activity was measured at pH 6.8 by the 
release of inorganic phosphate as described.49  
 
4.35. Crystal complex formation and X-ray crystallographic data collection and 
processing 
 
Native T-state RMGPb crystals were grown in the tetragonal lattice, space group P43212 and 
prior to data collection were soaked in a buffered solution (10 mM Bes, pH 6.7) with 20 mM 
of 6 (for 21 h) and 20 mM 19 (for 3.9 h). Diffraction data for both complexes were collected 
from single crystals at room temperature, using the synchrotron radiation source at SRS-
Daresbury Laboratory UK, beamline PX10.1 (λ = 0. 97976 Å). Integration of the reflections 
and data reduction was performed using the programs DENZO and SCALEPACK from HKL-
package.50  
 
4.36. Crystal structure determination 
 
The structures of RMGPb in complex with the ligands 6, 19, and 22 were determined by 
applying standard protocols for molecular replacement and refinement as implemented in 
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CCP4 suite51 using the programs PHASER and REFMAC. Ligand models were fitted to 2Fo-
Fc and Fo-Fc electron density maps after adjustment of their torsion angles using the program 
for molecular graphics COOT.52 The quality of the model was improved by alternate cycles of 
manual rebuilding with COOT where required and refinement with REFMAC. The data 
collection and refinement statistics along with the model quality of the complex structures are 
summarized in Table 3S.  
 
The stereochemistry of the protein residues was validated by PROCHECK and the analyses of 
the complex structures involving mapping of hydrogen bond and van der Waals interactions 
of the ligands with the residues lining the catalytic site was performed with CONTACT.51 A 
distance cut off at 3.3 Å between the electronegative atoms for H-bonds and 4.0 Å for van der 
Waals interactions was applied. The programme calculates the angle O…H…N (where the 
hydrogen position is unambiguous) and the angle source… oxygen-bonded carbon atom. 
Suitable values are 120° and 90°. The network of interactions is described in Tables 4S-12S. 
Structural comparisons were performed with the program LSQKAB51 by superposition of the 
atomic coordinates of the new complexes with RMGPb:spirohydantoin. The root mean square 
deviation in Cα positions were determined for residues (24-249), (261-281), (289-313), (326-
549), (558-830). The figures were prepared using the programs Chimera44 and Molsoft.47 The 
coordinates of the new structures in complex with RMGPb were deposited with the protein 
data bank PDBe (www.pdbe.org) with codes: 4ctm for 6, 4cto for 19, and 4ctn for 22. 
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Glucopyranosylidene-spiro-iminothiazolidinone, a New Bicyclic Ring System: Synthesis, 
Derivatization, and Evaluation for Inhibition of Glycogen Phosphorylase by Enzyme Kinetic and 
Crystallographic Methods 
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